XML 25 R52.htm IDEA: XBRL DOCUMENT v3.20.1
Equity Incentive Program - Stock Options and SSARs (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award    
Share-based Payment Arrangement, Expense $ 3.5 $ 6.7
SSARs    
Share-based Compensation Arrangement by Share-based Payment Award    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 0.0  
Number of Shares [Roll Forward]    
Beginning balance 596,537  
Granted 0  
Exercised 0  
Forfeited 0  
Expired 0  
Ending balance 596,537  
Exercised 596,537  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Options, Expired in Period, Weighted Average Exercise Price $ 0  
Weighted Average Grant Date Fair Value    
Beginning balance 22.72  
Granted 0  
Exercised 0  
Forfeited 0  
Ending balance 22.72  
Exercisable $ 22.72  
SARS and Options, Additional Disclosures    
SSARs, aggregate intrinsic value, outstanding $ 0.0  
SSARs, aggregate intrinsic value, exercisable $ 0.0  
SSARs, weighted average remaining contractual terms, outstanding 2 years 1 month 6 days  
SSARs, weighted average remaining contractual term, exercisable 2 years 1 month 6 days  
Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 8.6  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]    
Risk-free interest rate   2.44%
Dividend yield 0.00% 0.00%
Expected life (years)   4 years 6 months
Volatility   42.90%
Stock Options, Number of Shares    
Beginning balance 5,377,148  
Granted 886,799  
Exercised 14,475  
Forfeited (59,306)  
Expired (9,379)  
Ending balance 6,180,787  
Exercisable 4,523,952  
Stock Options, Weighted Average Exercise Price    
Beginning balance $ 17.51  
Granted 16.77  
Exercised 15.66  
Forfeited 17.00  
Expired 24.33  
Ending balance 17.40  
Exercisable $ 17.81  
SARS and Options, Additional Disclosures    
Options, aggregate intrinsic value, outstanding $ 3.1  
Options, aggregate intrinsic value, exercisable $ 3.1  
Options, weighted average remaining contractual term, outstanding 3 years 7 months 6 days  
Options, weighted average remaining contractual term, exercisable 2 years 7 months 6 days  
Minimum | Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]    
Risk-free interest rate 1.42%  
Expected life (years) 4 years 3 months 18 days  
Volatility 38.80%  
Fair value at date of grant $ 5.56 $ 6.22
Maximum | Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]    
Expected life (years) 4 years 6 months  
Volatility 40.60%  
Fair value at date of grant $ 5.95